Identification of basal-like carcinomas in clinical practice: "Triple zero/BRCA1-like" carcinomas;Identification en pratique clinique des carcinomes basal-like du sein: Des carcinomes «triple zéro/BRCA1-like»

Bulletin du Cancer

Volumn 97, Issue 3, 2010, Pages 357-363

  Vincent Salomon, A ^a   Macgrogan, G ^b   Charaffe Jauffret, E ^c   Jacquemier, J ^c   Arnould, L ^d  

^a INSTITUT CURIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Basal like carcinoma; Breast cancer; Gene expression profiling; PARP inhibitors; Phenotype

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE; PROTEIN KINASE B; TUMOR MARKER; TUMOR PROTEIN;

BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CHROMOSOME LOSS; CLINICAL PRACTICE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; MOLECULAR WEIGHT; MORPHOLOGY; ONCOGENE; P53 GENE; PHENOTYPE; PROGNOSIS; PTEN GENE; REVIEW; ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; METABOLISM; METHODOLOGY; MUTATION; NOMENCLATURE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENES, BRCA1; GENES, P53; HUMANS; MUTATION; NEOPLASM PROTEINS; PHENOTYPE; PROGNOSIS; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77950357625     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1062     Document Type: Review

References (39)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-752
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001 ; 98 : 10869-10874 (Pubitemid 32878711)
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 2003 ; 100 : 8418-8423 (Pubitemid 36842560)
4. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009 ; 360 : 790-800.
5. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006 ; 98 : 262-272 (Pubitemid 43264710)
6. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006 ; 7 : 96. (Pubitemid 43786485)
7. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 2008 ; 10 : R93.
8. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006 ; 66 : 4636-4644
9. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007 ; 9 : R65. (Pubitemid 350187481)
10. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 ; 10 : 5367-5374 (Pubitemid 39100473)
11. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002 ; 161 : 1991-1996 (Pubitemid 35434844)
12. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009 ; 117 : 273-280 Epub 2008 Sep 25.
13. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005 ; 207 : 260-268 (Pubitemid 41556449)
14. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007 ; 9 : R24. (Pubitemid 350215163)
15. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, Sarrio D, Martin-Guijarro Mdel C, Hernandez L, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 2007 ; 31 : 501-508 (Pubitemid 46569033)
16. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008 ; 26 : 2568-2581
17. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005 ; 18 : 1623-1631 (Pubitemid 41670663)
18. Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 2009 ; 22 : 291-298
19. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005 ; 24 : 4660-4671 (Pubitemid 41032603)
20. de Cremoux P, Vincent Salomon A, Liva S, Dendale R, Bouchind'homme B, Martin E, et al. p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma. J Natl Cancer Inst 1999 ; 91 : 641-643
21. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009 ; 69 : 663-671
22. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008 ; 10 : R101.
23. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006 ; 45 : 1033-1040 (Pubitemid 44435537)
24. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006 ; 10 : 529-541 (Pubitemid 44854748)
25. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. JNCI Cancer Spectrum 2003 ; 95 : 1482-1485 (Pubitemid 37279334)
26. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006 ; 25 : 5846-5853 (Pubitemid 44453440)
27. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007 ; 26 : 2126-2132 (Pubitemid 46514749)
28. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118
29. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007 ; 13 : 2329-2334 (Pubitemid 46698581)
30. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005 ; 11 : 5678-5685 (Pubitemid 41170290)
31. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP-ribose) polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008 ; 26 : 3785-3790
32. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 ; 361 : 123-134
33. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008 ; 8 : 363-369
34. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008 ; 18 : 80-86 (Pubitemid 351694447)
35. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005 ; 5 : 388-393
36. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982 ; 31 : 11-24. (Pubitemid 13215192)
37. Gusterson B. Do 'basal-like' breast cancers really exist? Nat Rev Cancer 2009 ; 9 : 128-134
38. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998 ; 433 : 119-129 (Pubitemid 28401168)
39. Moinfar F. Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology 2008 ; 75 : 119-131